Investigating tau protein levels in mouse brains to find treatments for Alzheimer's disease
Official title: In vivo Screening Methods Targeting Levels of Tau Protein within Mouse Brains
Funded at Baylor College of Medicine · NIH-11141226 · Data updated 2026-11-12
This study is looking at how a protein called tau affects Alzheimer's Disease and aims to find new ways to adjust its levels in the brain to help improve treatment options for people with the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $280,875 |
| NIH project number | 5R21AG088501-02 |
| Project ID | NIH-11141226 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease or other tau-related neurodegenerative conditions.
✕Less likely to help
Patients with neurodegenerative diseases not associated with tau protein accumulation may not benefit from this research.
What this research studies
This research focuses on understanding the role of tau protein in neurodegenerative diseases, particularly Alzheimer's Disease (AD). By using advanced in vivo screening methods in mouse models, the researchers aim to identify how tau protein levels can be modulated to potentially improve disease outcomes. The study seeks to develop more effective therapeutic strategies by bypassing traditional cell-based screening methods, which often fail to accurately reflect the complexities of human brain biology. This innovative approach could lead to the discovery of new targets for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce tau protein accumulation, potentially slowing the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting tau protein levels as a therapeutic strategy, indicating that this approach could be a meaningful advancement in the field.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Kim, Jiyoen — Baylor College of Medicine
- Study coordinator: Kim, Jiyoen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.